Last reviewed · How we verify
SU014813
At a glance
| Generic name | SU014813 |
|---|---|
| Sponsor | Pfizer |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Trial Of SU14813 In Patients With Advanced Solid Malignancies (PHASE1)
- Study Of The Efficacy And Safety Of SU-014813 In Patients With Metastatic Breast Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SU014813 CI brief — competitive landscape report
- SU014813 updates RSS · CI watch RSS
- Pfizer portfolio CI